Clinical trial
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
NCT00003765 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003765 |
|---|---|
| Title | O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors |
| Official title | A Trial of 06-BG and BCNU in Children With CNS Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | O6-benzylguanine, carmustine |
| Enrollment | 36 |
| Start date | May 1, 1999 |
| Primary completion | Mar 1, 2006 |
| First posted | Apr 27, 2004 |
| Last update posted | Feb 5, 2013 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: